Clinical journal of the American Society of Nephrology : CJASN
-
Clin J Am Soc Nephrol · May 2013
Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.
Circulating fibroblast growth factor-23 is associated with adverse cardiovascular outcomes in CKD and non-CKD individuals, but the underlying mechanism remains unclear. This study tested whether this association is independent of mineral metabolism and indices of subclinical cardiovascular pathology. ⋯ Fibroblast growth factor-23 is an independent predictor of cardiovascular events in the community, even after accounting for mineral metabolism abnormalities and subclinical cardiovascular damage. Circulating fibroblast growth factor-23 may reflect novel and important aspects of cardiovascular risk yet to be unraveled.